Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Medical technology & services

Sativa Group appoints new member to medical advisory board

Clive Page’s main research interests are in the pharmacology of inflammation and respiratory disease

Sativa Group PLC (LON:SATI) has appointed Clive Page, professor of pharmacology at King's College London, to its medical advisory board.

In a statement, the NEX-listed CBD wellness and medicinal cannabis company noted that Page’s main research interests are in the pharmacology of inflammation and respiratory disease, having published over 300 scientific papers and book chapters, and he is a fellow of the Royal Society of Biology and an honorary fellow of the British Pharmacological Society.

READ: Sativa inks exclusive deal with leading sales and marketing company for CBD range

Nick Horniman, director of regulatory affairs at Sativa commented: “Professor Page is an eminent research scientist and will add to Sativa's experience, interest and understanding in cannabis-based medical products."

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK